A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Key Inclusion Criteria:

1. Local histologic confirmation of FL grade 1-3a or MZL (nodal, splenic, or extranodal MZL) as assessed by the investigator, as described in the protocol.

2. Must have refractory disease or relapsed after at least 1 prior line (with aduration of at least 2 cycles) of systemic chemo-immunotherapy or immunotherapy.Prior systemic therapy should have included at least one anti-Cluster ofDifferentiation 20 (CD20) monoclonal antibody and participant should meet indicationfor treatment, as described in the protocol.

3. Have measurable disease on cross sectional imaging documented by diagnostic ComputedTomography [CT], or magnetic resonance imaging [MRI] imaging, as described in theprotocol.

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

5. Adequate hematologic and organ function, as described in the protocol.

6. All study participants must:

7. Have an understanding that lenalidomide could have a potential teratogenicrisk.

8. Agree to abstain from donating blood while taking study drug therapy and for 28days after discontinuation of lenalidomide.

9. Agree not to share study medication with another person.

10. Agree to be counseled about pregnancy precautions and risk of fetal exposureassociated with lenalidomide.

Key Exclusion Criteria:

1. Primary Central Nervous System (CNS) lymphoma or known involvement (either currentor prior history of CNS involvement) by non-primary CNS NHL, as described in theprotocol.

2. Participants with histological evidence of transformation to a high-grade or diffuselarge B-cell lymphoma, or any histology other than FL grade 1-3a or MZL.

3. History of or current relevant CNS pathology, as described in the protocol.

4. A malignancy other than NHL unless the participant is adequately and definitivelytreated and is cancer free for at least 3 years, with the exception of localizedprostate cancer treated with hormone therapy or local radiotherapy (ie, pellets),cervical carcinoma in situ, breast cancer in situ, or nonmelanoma skin cancer thatwas definitively treated.

5. Any other significant active disease or medical condition that could interfere withthe conduct of the study or put the participant at significant risk, as described inthe protocol.

6. Allergy/hypersensitivity to study drugs or excipients. as described in the protocol.

7. Active infection as defined in the protocol.

Note: Other protocol-defined Inclusion/Exclusion criteria apply